Literature DB >> 24612680

Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.

Jun Ho Lee1, Yooseok Kim, Yeon Won Park, Dong-Gi Lee.   

Abstract

INTRODUCTION: Scant data are available concerning the relationship between lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and total serum testosterone level (TT) in eugonadal state. AIM: We performed this study to evaluate the relationship between LUTS/BPH and TT in eugonadal men.
METHODS: A cross-sectional study was conducted that included a total of 2,308 eugonadal (TT ≥ 3.0 ng/mL) male police officers aged 40-59 years who had participated in a health examination. LUTS/BPH were assessed by prostate-specific antigen level, international prostate symptom score (IPSS), total prostate volume (TPV), maximal flow rate (Qmax), postvoid residual urine volume (PVR), and a full metabolic workup. We then investigated their relationship using the Spearman correlation test, multiple linear regression, and logistic regression analyses. MAIN OUTCOME MEASURES: Associations of TT with IPSS, Qmax, and PVR.
RESULTS: The median age and TT level were 49.0 years and 5.37 ng/mL, respectively. The TT level showed significant positive correlations with Qmax (r = 0.043, P = 0.048) and a significant negative correlation with PVR (r = -0.050, P = 0.022). No significant correlation was found between TT and TPV or IPSS. However, Qmax and PVR as well as TPV and IPSS did not significantly correlate with TT after adjusting for age and/or metabolic syndrome. On logistic regression, no significant difference was found in surrogate measures of LUTS/BPH (TPV > 30 mL, IPSS > 7, Qmax < 15 mL/second, and PVR > 50 mL) between the highest quartile TT group (median: 7.07 ng/mL) and the lowest quartile group (median: 3.92 ng/mL).
CONCLUSION: In our study, TT was not clearly correlated with LUTS/BPH in middle-aged eugonadal men.
© 2014 International Society for Sexual Medicine.

Entities:  

Keywords:  International Prostate Symptom Score; Lower Urinary Tract Symptoms; Maximum Urinary Flow Rate; Testosterone; Total Prostate Volume

Mesh:

Substances:

Year:  2014        PMID: 24612680     DOI: 10.1111/jsm.12489

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Testosterone Replacement Therapy on the Natural History of Prostate Disease.

Authors:  Aaron Moore; Michael J Butcher; Tobias S Köhler
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

2.  The Effect of Transdermal Testosterone Administration on Lower Urinary Tract Symptoms and Erectile Dysfunction: A Prospective, Randomized, Placebo-Controlled Trial.

Authors:  Cem Yucel; Mehmet Zeynel Keskin; Cetin Levent Peskircioglu
Journal:  Curr Urol       Date:  2017-11-30

3.  Testosterone therapy: a friend or a foe for the aging men with benign prostatic hyperplasia?

Authors:  Giulia Rastrelli; Linda Vignozzi; Mario Maggi
Journal:  Asian J Androl       Date:  2020 May-Jun       Impact factor: 3.285

4.  Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.

Authors:  Katarzyna Grzesiak; Aleksandra Rył; Irena Baranowska-Bosiacka; Iwona Rotter; Barbara Dołęgowska; Marcin Słojewski; Olimpia Sipak-Szmigiel; Weronika Ratajczak; Anna Lubkowska; Emilia Metryka; Małgorzata Piasecka; Maria Laszczyńska
Journal:  Clin Interv Aging       Date:  2018-08-03       Impact factor: 4.458

5.  Correlation Between Testosterone Replacement Treatment and Lower Urinary Tract Symptoms.

Authors:  Min Ho Lee; Yu Seob Shin; Sung Chul Kam
Journal:  Int Neurourol J       Date:  2021-01-19       Impact factor: 2.835

6.  A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.

Authors:  Yu Wu; Hong Pan; Wei-Ming Wang; Ding Xu; Liang Zhang; Zheng-Qin Gu; Qiang Bai; Jun Qi; He-Feng Huang
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.